Taylor Andelman

TAYLOR ANDELMAN focuses her practice on healthcare regulatory, compliance, and transactional matters for a wide range of life sciences and health care provider clients. This includes advising clients on fraud and abuse issues involving the federal Anti-Kickback Statute, Medicare and Medicaid coverage and reimbursement, the 340B program, government price reporting laws, market access, patient assistance programs, and the development of healthcare compliance programs.

Taylor regularly counsels pharmaceutical manufacturers on state drug price transparency matters and issues related to clinical trials. Taylor also leads regulatory due diligence reviews for private equity and M&A transactions in the healthcare industry.

Taylor earned her J.D., cum laude, from Georgetown University Law Center where she served as managing editor of the Food and Drug Law Journal. She received a M.P.H. from the John Hopkins Bloomberg School of Public Health and a B.A., cum laude, from the University of California, Berkeley. During her time at Georgetown Law, Taylor served as a legislative fellow in the U.S. House of Representatives.

• Jiangsu Hengrui Pharmaceuticals Co., Ltd. in connection with a license agreement with Novo Nordisk for HRS-1596. Novo will obtain exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding the Chinese mainland, the Hong Kong Special Administrative Region (SAR), the Macao SAR, and the Taiwan region. The potential total value of the agreement is up to US$2.6 billion contingent on the achievement of applicable development, regulatory, and commercial milestones. This includes a US$300 million upfront payment. In addition, Hengrui Pharma is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory.